TABLE 2.

Neutralization phenotype of SIVgor

VirusbNeutralization titeraCoreceptor used
sCD4 (nM)HIVIGcClade B plasma poolClade C plasma poolGroup O plasmaGroup O plasmab122G122F54E10Z13e1T-20T-1249447-52D447-52D sCD4F425-B4e8F425-B4e8 sCD417b17b sCD419e19e sCD421c21c sCD4Anti-CD4 MAbTAK-779 (μM)
SIVgor (CP2139.287)154>100020<20<20<20>50>504.6>50>500.0010.004>25>25>25>25>10>10>10>10>10>100.230.033R5
HIV-1_O (97US08692A)21>1000NAdNANANA>50>50>50>50>500.0100.08412.47>25>25>25>10>10>10>10>10>10>20.201R5
HIV-1_N (YBF30)498>1000<20<20<20<20>50>50>5034.63>500.0160.026>25>25>25>25>10>10>10>10>10>100.190.034R5
HIV-1_M (NL4.3)27163035883<200.010.850.441.35>500.1020.0010.020.01>25>250.170.26>10>100.551.11.89>10X4
HIV-1_M (YU2)14891178267<20<201.63>50>50>50>500.1430.04410.240.02>251.68>10>10>10>10>10>100.170.007R5
  • a Neutralization titers are expressed as the reciprocal 50% inhibitory plasma dilutions or the IC50s for the respective Env ligands in one representative experiment (performed in duplicate). All titers are given in μg/ml unless otherwise stated.

  • b CP2139.287, NL4.3, and YU2 are molecular clones of HIV-1 strains. 97US08692A and YBF30 are primary HIV-1 isolates.

  • c HIVIG, pooled human immunoglobulin purified from plasma samples of healthy HIV-1-infected individuals.

  • d NA, not available.